The latest release of Genedata Screener business software increases data quality and accelerates project cycles
BASEL, Switzerland, March 4, 2024 /PRNewswire-PRWeb/ — Genedata, a leading provider of enterprise software solutions for biopharmaceutical research and development, today announced the new release of Genedata Screener®, its enterprise platform for automated analysis of trial data and consolidated trial information management across the enterprise. The new version features a new module, Test Performance Monitoring, the first commercially available solution for monitoring test data quality in the context of historical data. Included in the most comprehensive analytical assay platform on the market, Genedata Screener 21 sets new standards for data quality assessment and automated data processing that produce higher quality results, accelerated workflow combined with increased consistency, improved scientific efficiency and shortened timelines for molecule discovery and development.
Developed in close collaboration with leading biopharma companies, Genedata Screener 21 offers a new integrated solution for continuous assay quality assessment, enabling automated identification of experimental problems without delay. Biopharmaceutical R&D organizations must ensure that the routine analyzes they perform on their portfolio of molecules remain sensitive and consistent over time, providing reliable data for decision making. Low reliability or efficiency of bioassays has costly consequences. Without a suitable business solution, scientists spend hours manually collecting test performance data, often jumping between software tools. Screener’s routine assessment of assay performance using the new assay performance monitoring module follows industry best practice and ensures assay quality standards are met without the need for manual data collection. This guarantees high-quality, consistent results from long-term tests for discovery and development projects.
With this release, Screener now enables a fully automated, unattended workflow starting with data capture and ending with reporting results to the data warehouse. This automation also enables the automatic generation of ELN records to document experimental procedures consistently and without hands-on preparation. The solution eliminates manual processing steps and file handling and eliminates handover delays. Moreover, to ensure that only high-quality data is automatically reported without human review, the Screener checks whether data quality meets specific criteria defined by corporate business rules. The latest release dramatically shortens the time from test execution to decision, speeding up project cycles and raising the quality of the output so that project teams can base their decisions on the best possible quality data.
Using artificial intelligence, biophysical analyzes such as surface plasmon resonance (SPR) and biolayer interferometry (BLI) can be analyzed in Screener faster and in an unbiased manner. The new version integrates an AI-based classifier that automates the classification of binding profiles produced by SPR and BLI measurements. Automating profile classification reduces scientific review time by more than 80% of previous workflow time and saves days of manual analysis in campaigns with thousands of samples. It also reduces the bias and errors from manual assessment of many profiles that high-throughput screening typically produces. AI-based automation of SPR/BLI data analysis and quality control increases the repeatability, consistency and reliability of these key inputs for molecular profiling and decisions to progress drug discovery, improving workflow efficiency to better navigate the right candidate.
“At Genedata, we continue to turn into action our commitment to enable dramatic increases in productivity and quality in Biopharma research and development,” it said. Othmar PfannesPh.D., executive director of Genedata. “By enabling new automated workflows to achieve higher data quality standards, increased efficiency and shorter project cycles, this release solidifies Genedata’s position as the digital backbone and foundation for more successful biopharmaceutical research and development.”
O Genedata
Genedata turns data into intelligence with innovative software solutions that incorporate extensive knowledge of the biopharmaceutical R&D domain. Multinational biopharmaceutical organizations and leading biotechs around the world rely on Genedata to digitize and automate complex, data-rich R&D processes. From early discovery through to the clinic, Genedata solutions help maximize ROI on R&D spend. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singaporeand Tokyo.
http://www.genedata.com
LinkedIn | Twitter | YouTube
Contact
Allison Short
Genedata
Public relations
[email protected]
Waiver
Statements in this press release that refer to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks related to uncertainties related to contract cancellation, development risks, competitive factors, uncertainties related to customer orders , demand for products and services, market development for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly announce the results of any changes to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names listed are trademarks of their respective companies.
SOURCE Genedata
